Leverkusen, Germany - December 20, 2013, Leverkusen, Germany - Bayer AG announces the appointment of Kemal Malik to the board of management of Bayer AG, effective February 1, 2014.
Article continues below
Mr. Malik has been a member of the Bayer HealthCare Executive Committee, Head of Global Development and Chief Medical Officer since July 1, 2007. Mr. Malik studied medicine at Charing Cross and Westminster Medical School (University of London), graduating as a Bachelor of Medicine, Bachelor of Surgery (MB, BS) in 1987.
He subsequently spent several years in clinical medicine at the Northwick Park Clinical Research Centre, London. He then held various positions of increasing responsibility in medical affairs and clinical development at Bristol-Myers Squibb in the United Kingdom.
Mr. Malik joined Bayer in 1995 as head of Metabolism and Oncology Europe in what was then the Pharmaceuticals Business Group. He subsequently served as Head of Global Medical Development before being appointed Head of Global Development.
Mr. Malik will be responsible for Innovation and take over responsibility for the North America region. He is to succeed Wolfgang Plischke effective April 30, 2014, upon Professor Plischke’s retirement as of that date.
Professor Plischke joined Bayer in 1980 and has been a member of the Board of Management since March 1, 2006. He is responsible for Innovation, Technology and Sustainability and the Asia/Pacific region.
Mr. Plischke studied biology at Hohenheim University before starting his career in 1980 with Bayer’s subsidiary Miles Diagnostics. In 1995, he became President of Bayer Yakuhin Ltd., Japan, with responsibility for Pharmaceuticals and Consumer Care. In 2000, he took over as head of the Pharmaceuticals Business Group in North America.
In January 2002, he was appointed head of the Pharmaceuticals Business Group at Bayer AG with responsibility for the global business with prescription medicines. From July 1, 2002, until his appointment to the Board of Management of Bayer AG, Mr. Plischke was a member of the Bayer HealthCare Executive Committee and head of the Pharmaceuticals Division.
Mr. Plischke also holds a number of offices outside of Bayer AG. He is a member of the boards of the Walter Siegenthaler Society, the German Asia-Pacific Business Association and the Robert Koch Foundation. In addition, he is a member of the boards of trustees of the Paul Ehrlich Foundation and the German Chemical Industry Fund.
Mr. Plischke is also Vice President of the European Chemical Industry Council (CEFIC), Chairman of the CEFIC Research and Innovation Programme and Chairman of the Healthcare Committee of the Federation of German Industries (BDI). In July 2011, Mr. Plischke was appointed honorary professor for Business Chemistry at the Ludwig Maximilian University of Munich. ■
Predominant upper-level ridging stretching from the Southwest to the southern High Plains will allow for another day of record-breaking heat across parts of Nevada and Arizona today.